Mount Sinai launched the Precision Immunology and Experimental Medicine Trial Organization to accelerate early-phase clinical trials for inflammatory and autoimmune disorders. The initiative is built to support faster start-up and execution of investigator-led experimental medicine programs, aiming to reduce the friction that commonly slows early development. The platform focuses on trial readiness in areas where patient selection, biomarkers, and immunology-specific endpoints often require specialized infrastructure and coordinating expertise. For biotech sponsors, the move signals expanding academic capacity for structured early trials and may increase competition for enrollment-ready programs with strong translational readouts.
Get the Daily Brief